- Home
- RARE
as 11-11-2025 3:41pm EST
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | 3.2B | IPO Year: | 2014 |
| Target Price: | $87.00 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.81 - $53.04 | Next Earning Date: | 11-04-2025 |
| Revenue: | $630,598,000 | Revenue Growth: | 20.63% |
| Revenue Growth (this year): | 19.65% | Revenue Growth (next year): | 23.65% |
Stock Insider Trading Activity of Ultragenyx Pharmaceutical Inc. (RARE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Horn Howard | RARE | Chief Financial Officer | Oct 13 '25 | Sell | $31.51 | 7,942 | $250,252.42 | 98,227 | |
| Parschauer Karah Herdman | RARE | EVP and Chief Legal Officer | Sep 12 '25 | Sell | $31.17 | 2,450 | $76,366.50 | 73,271 | |
| Huizenga Theodore Alan | RARE | SVP, Chief Accounting Officer | Sep 5 '25 | Sell | $31.39 | 84 | $2,636.76 | 50,306 |
Latest Ultragenyx Pharmaceutical Inc. News
RARE Breaking Stock News: Dive into RARE Ticker-Specific Updates for Smart Investing
Zacks
a month ago
Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength?
GlobeNewswire
a month ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
a month ago
Ultragenyx Pharmaceutical (RARE): Valuation Perspectives Following Regulatory Milestones and Pipeline Progress
Simply Wall St.
a month ago
How Might Ultragenyx (RARE) Leverage Dealmaking Expertise to Shape Its Long-Term Growth Strategy?
Insider Monkey
a month ago
Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline
MT Newswires
a month ago
Ultragenyx Names Eric Olson as Chief Business Officer
GlobeNewswire
a month ago
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
Zacks
2 months ago
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
Compare RARE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RARE Ultragenyx Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.